In August 2020, the Department of Justice filed a lawsuit against Teva Pharmaceuticals alleging the company's payment of patients' cost-sharing obligations for one of its high-priced drugs to treat multiple sclerosis. What are your thoughts on this case and the conduct as alleged, particularly in light of the fact that OIG issued guidance many years ago regarding the regulatory risk of such conduct